According to research, Tesamorelin, known under the name Egrifta is a synthetic version of growth hormone releasing hormone. Reports show that it is made of 44 amino acids and has a trans-3-hexenoic acid group.
Tesamorelin is a white powder that would then need to be reconstituted to be used. Paradigm Peptide offers Tesamorelin in 10mg vials. Once the peptide is reconstituted, it should be used immediately. When reconstituted, the peptide should be clear in color and free of any particles.
Long Term Tesamorelin Use For HIV Abdominal Fat Accumulation
The study aimed to evaluate the long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with central fat accumulation. Initially, patients were randomized to receive either tesamorelin or placebo for 26 weeks. After this period, patients on tesamorelin either continued treatment or switched to placebo, while those on placebo began tesamorelin therapy for an additional 26 weeks. Safety assessments included monitoring adverse events and glucose parameters.
Tesamorelin was well tolerated throughout the study, with adverse event rates comparable to the initial phase. Glucose levels remained stable over 52 weeks, and reductions in visceral adipose tissue and triglycerides were sustained. Total cholesterol showed sustained improvements, while high-density lipoprotein decreased slightly. Notably, upon discontinuation of tesamorelin, VAT reaccumulated. [3]
In conclusion, treatment with tesamorelin demonstrated long-term safety and sustained reductions in VAT and triglycerides over 52 weeks without adverse effects on glucose levels. However, the beneficial effects on VAT were not maintained after treatment cessation, indicating the need for continued therapy to sustain improvements in body composition among HIV patients with central fat accumulation. [3]
Study Of Tesamorelin Treatments On Non-Alcoholic Fatty Liver Disease In HIV
The study aimed to evaluate the effects of tesamorelin on liver fat and histology in individuals with HIV and non-alcoholic fatty liver disease (NAFLD), a significant comorbidity in this population without established pharmacological treatments. Conducted in the USA, this randomized, double-blind, multicenter trial enrolled individuals with HIV and a hepatic fat fraction (HFF) of 5% or more by proton magnetic resonance spectroscopy. Participants were randomly assigned to receive either tesamorelin once daily or placebo for 12 months, followed by a 6-month open-label phase with all participants receiving tesamorelin.
The primary endpoint was the change in HFF between baseline and 12 months, with glucose levels monitored as the primary safety endpoint. Of the 61 enrolled patients, 30 received tesamorelin and 30 received placebo.
The tesamorelin group exhibited a greater reduction in HFF compared to the placebo group, with a relative reduction of -37% from baseline after 12 months. Notably, 35% of individuals in the tesamorelin group achieved an HFF of less than 5%, compared to 4% in the placebo group. Changes in fasting glucose and glycated hemoglobin did not differ significantly between the groups at 12 months. [5]
While individuals in the tesamorelin group experienced more localized injection site complaints, none were deemed serious. The findings suggest that tesamorelin may be effective in reducing liver fat in individuals with HIV and NAFLD, with manageable side effects, thus holding promise as a potential treatment option for this population. [5]
Reviews
There are no reviews yet.